We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
T Cells, Interleukin-2 and Systemic Lupus Erythematosus—From Pathophysiology to Therapy.
- Authors
Mak, Anselm
- Abstract
The phenotypic and functional complexities of T cells engender complicated and often confusing concepts as to how T cells ignite, accelerate and brake the inflammatory processes involved in systemic lupus erythematosus (SLE), let alone the plasticity of T cells that takes place under different immunological contexts. Nevertheless, being one of the prime survival factors of T cells, interleukin (IL)-2 plays a potentially critical role in many immunological scenarios during the pathophysiological process of SLE. Here, the pathophysiology of lupus T cells and current, as well as ongoing, therapeutic approaches of SLE that involve low-dose IL-2 administration will be highlighted. The mechanisms of IL-2 deficiency in SLE pathophysiology, the effects of low-dose IL-2 on T cells and restoration of lupus manifestations in murine SLE models, as well as the efficacy and safety of clinical trials that evaluated low-dose IL-2-containing regimens in patients with SLE will be discussed.
- Subjects
T cells; SYSTEMIC lupus erythematosus; INTERLEUKIN-2; PATHOLOGICAL physiology; INTERLEUKIN-7
- Publication
Cells (2073-4409), 2022, Vol 11, Issue 6, p980
- ISSN
2073-4409
- Publication type
Article
- DOI
10.3390/cells11060980